Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma

被引:0
|
作者
Tam, Andrew [1 ]
Ladbury, Colton [1 ]
Kassardjian, Ari [1 ]
Modi, Badri [2 ]
McGee, Heather [1 ]
Melstrom, Laleh [3 ]
Margolin, Kim [4 ]
Xing, Yan [5 ]
Amini, Arya [1 ]
机构
[1] City Hope Comprehens Canc Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Comprehens Canc Ctr, Dept Dermatol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] City Hope Comprehens Canc Ctr, Dept Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA
[4] St Johns Canc Inst, 2121 Santa Monica Blvd, Santa Monica, CA 90404 USA
[5] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, 1500 E Duarte Rd, Duarte, CA 91010 USA
关键词
melanoma; immunotherapy; TVEC; radiotherapy; IMMUNOTHERAPY; RESPONSES;
D O I
10.3390/cancers16111951
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Talimogene laherparepvec (TVEC), a modified virus, is a local injected therapy that has been demonstrated to be an effective treatment in patients with advanced melanoma. Recent reports have suggested that radiation treatment (RT) may activate the immune system when combined with TVEC to further improve both local and systemic responses. However, studies on the combined effect of TVEC and RT remain limited. Here, we reviewed twenty melanoma patients who had received TVEC and RT (fourteen patients to the same region and six patients to different regions of the body) and found a benefit in progression-free survival (PFS) and time to distance metastasis (DM) with a combined regional approach of TVEC and RT. These results suggest that the regional approach of using these two treatment modalities may confer a therapeutic benefit.Abstract Talimogene laherparepvec (TVEC) is a genetically modified oncolytic herpes simplex virus (HSV-1) that is used for the intralesional treatment of advanced or metastatic melanoma. Given that TVEC produces the granulocyte-macrophage colony-stimulating factor (GM-CSF), recent reports have suggested that radiation treatment (RT) given in conjunction with TVEC may provide synergistic immune activation at the site, and possibly systemically. However, studies on combining RT with TVEC remain limited. We conducted a retrospective review of melanoma patients from a single cancer center who received TVEC and RT in the same region of the body and compared them to patients who received TVEC with RT at another site (other than the site of TVEC injection). Between January 2015 and September 2022, we identified twenty patients who were treated with TVEC and RT; fourteen patients received TVEC and RT in the same region, and six had treatments in separate regions. Regions were determined at the time of analysis and were based on anatomic sites (such as arm, leg, torso, etc.). Kaplan-Meier analysis of progression-free survival (PFS), analyses of time to distant metastasis (DM), overall survival (OS), and locoregional control (LRC), and the corresponding log-rank test were performed. With a median follow-up of 10.5 months [mos] (range 1.0-58.7 mos), we found an improvement in PFS with TVEC and RT in the same region compared to different regions, which were 6.4 mos (95% CI, 2.4-NR mos) and 2.8 mos (95% CI, 0.7-4.4 mos), respectively; p = 0.005. There was also a significant improvement in DM when TVEC and RT were used in the same region compared to different regions: 13.8 mos (95% CI, 4.6-NR mos) and 2.8 mos (95% CI, 0.7-4.4 mos), respectively (p = 0.001). However, we found no difference in overall survival (OS) between patients who had TVEC and RT in the same region (19.0 mos, 95% confidence interval [CI], 4.1-not reached [NR] mos) and those who received treatments in different regions (18.5 mos, 95% CI, 1.0-NR mos); p = 0.366. There was no statistically significant improvement in locoregional control (LRC) in patients who had TVEC and RT in the same region was 26.0 mos (95% CI, 6.4-26.0 mos) compared to patients who received TVEC and RT in different regions (4.4 mos) (95% CI, 0.7-NR mos) (p = 0.115). No grade 3 or higher toxicities were documented in either group. Overall, there were improvements in PFS and DM when TVEC and RT were delivered to the same region of the body compared to when they were used in different regions. However, we did not find a significant difference in locoregional recurrence or OS. Future studies are needed to assess the sequence and timing of combining RT and TVEC to potentially enhance the immune response both locally and distantly.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma
    Yamazaki, Naoya
    Isei, Taiki
    Kiyohara, Yoshio
    Koga, Hiroshi
    Kojima, Takashi
    Takenouchi, Tatsuya
    Yokota, Kenji
    Namikawa, Kenjiro
    Yi, Min
    Keegan, Alissa
    Fukushima, Satoshi
    CANCER SCIENCE, 2022, 113 (08) : 2798 - 2806
  • [32] Talimogene laherparepvec is an effective salvage therapy for advanced melanoma: A real-world study
    Yamada, M. M.
    Chandrasekhar, S.
    Chen, R.
    Doolittle-Amieva, C.
    Gooley, T.
    Park, S. Y.
    Chen, D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S28 - S28
  • [33] Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
    Bommareddy, Praveen K.
    Patel, Anand
    Hossain, Saamia
    Kaufman, Howard L.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (01) : 1 - 15
  • [34] Talimogene laherparepvec monotherapy for head and neck melanoma patients
    Franke, Viola
    Stahlie, Emma H. A.
    Klop, Willem M. C.
    Zuur, Charlotte L. L.
    Berger, Danique M. S.
    van der Hiel, Bernies
    van de Wiel, Bart A. A.
    Wouters, Michel W. J. M.
    van Houdt, Winan J. J.
    van Akkooi, Alexander C. J.
    MELANOMA RESEARCH, 2023, 33 (01) : 66 - 70
  • [35] Dermoscopic Guidance of Talimogene Laherparepvec Injection for Metastatic Melanoma
    Khalsa, Amrit
    Bacik, Lindsay
    Pameijer, Colette
    Seiverling, Elizabeth
    DERMATOLOGIC SURGERY, 2018, 44 (07) : 1026 - 1028
  • [36] NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma
    Adam, Jane
    Robertson, Janet
    Donegan, Eleanor
    Voicechovskaja, Irina
    LANCET ONCOLOGY, 2016, 17 (11): : 1485 - 1486
  • [37] Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma
    Henning, Ania
    Agnese, Doreen
    Chung, Catherine G.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2021, 48 (11) : 1423 - 1426
  • [38] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Casey Quinn
    Qiufei Ma
    Amber Kudlac
    Stephen Palmer
    Beth Barber
    Zhongyun Zhao
    Advances in Therapy, 2016, 33 : 643 - 657
  • [39] Real-World Safety and Efficacy of Talimogene Laherparepvec Therapy in Older Adults with Advanced Melanoma
    Herb, Joshua
    Jones, Paige
    Archer, Dion
    Meyers, Michael
    Stitzenberg, Karyn
    Long, Patricia
    Collichio, Frances
    Ollila, David
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S212 - S212
  • [40] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Quinn, Casey
    Ma, Qiufei
    Kudlac, Amber
    Palmer, Stephen
    Barber, Beth
    Zhao, Zhongyun
    ADVANCES IN THERAPY, 2016, 33 (04) : 643 - 657